Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Duality Biotherapeutics, Inc. ( (HK:9606) ) is now available.
Duality Biotherapeutics has convened an extraordinary general meeting for April 29, 2026 in Shanghai to seek shareholder approval for an RMB share issuance of up to 15,779,190 shares, subject to regulatory clearances. The meeting will also consider amendments to its articles of association and new procedural rules that will become effective upon the RMB shares’ listing on the Sci-Tech Board.
Resolutions to be voted on include authorizing the board to manage all matters related to the RMB share issue, approving plans for dealing with accumulated losses, price stabilization, and dividend returns over the three years following the issuance. Shareholders will also review proposals on the use of proceeds, remedial measures for any post-issue return dilution, and binding undertakings tied to the RMB listing, signaling a comprehensive preparation for a dual-market capital structure in Hong Kong and mainland China.
The most recent analyst rating on (HK:9606) stock is a Buy with a HK$383.47 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.
More about Duality Biotherapeutics, Inc.
Duality Biotherapeutics, Inc. is a Cayman Islands-incorporated biopharmaceutical company whose shares are listed in Hong Kong. The company operates in the biotechnology and life sciences sector, focusing on the development and commercialization of innovative therapeutic products, and is seeking broader access to China’s capital markets via an RMB share listing on Shanghai’s Sci-Tech Board.
Average Trading Volume: 817,621
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$27.31B
Find detailed analytics on 9606 stock on TipRanks’ Stock Analysis page.